Nrx pharmaceuticals, inc. (nasdaq: nrxp) announces the incorporation of hope therapeutics, inc., and planned share dividend/royalty coupon

Hope therapeutics is dedicated to bringing nrx-100 (iv ketamine) for suicidal depression to patients company to be initially owned by nrx and current nrx shareholders via a planned tax-free dividend a new drug application (nda) for nrx-100 is expected to be filed in 1h24 initiating actions to gain a public listing  shareholder meeting planned for february 7, 2024, is cancelled, and will be rescheduled, if necessary; company expects to convene a new meeting to vote on the hope transaction and share dividend, subject to board approval radnor, pa. , feb. 5, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced the incorporation of hope therapeutics™, a biotechnology company dedicated to bringing nrx-100 (iv ketamine), which will be re-designated htx-100, a potentially lifesaving treatment option for patients with suicidal depression.
NRXP Ratings Summary
NRXP Quant Ranking